In order to find, create, and market innovative antibody-based therapies for rare illnesses, AbCellera and Rallybio Corporation have announced their strategic agreement. In this multi-year, multi-target cooperation, Rallybio’s clinical and commercial experience in rare illnesses will be combined with AbCellera’s antibody discovery engine to identify the best clinical candidates and eventually provide medicines to patients.
“It’s clear that we need to accelerate drug development for rare diseases to address the enormous unmet medical need for these patients. Rallybio’s team has decades of experience in sourcing, identifying, and evaluating therapeutic targets. By bringing together Rallybio’s deep expertise in rare diseases with AbCellera’s integrated technology for delivering clinical leads with unmatched precision and speed, this partnership creates a unique advantage that we believe will deliver new and transformative medicines to patients.”
Carl Hansen, Ph.D., founder, and CEO of AbCellera
Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, stated that “AbCellera’s clinically validated discovery engine will boost our efforts in discovering additional rare illness candidates to add to our existing pipeline.” “We are thrilled to forge this alliance and look forward to working closely with our colleagues at AbCellera as we develop breakthrough therapeutics together,” the company stated.
AbCellera and Rallybio will choose jointly up to five potential therapeutic targets for rare diseases that will be co-developed under the parameters of the partnership. Through the partnership, Rallybio will be able to add product candidates to its current pipeline, and AbCellera will have the ability to carry out process development and clinical production operations. The initial initiative of the cooperation will be devoted to meeting the critical unmet treatment requirements of patients with uncommon metabolic illnesses.
About AbCellera Biologics Inc.
A technological business called AbCellera examines, decodes, and analyses natural immune systems to uncover antibodies that its collaborators can turn into medicines to cure and prevent the disease from happening. AbCellera collaborates with businesses of all sizes, from big pharmaceuticals to little biotechs, to help them create drugs more rapidly, more affordably, and more successfully.
For patients with severe and uncommon disorders, Rallybio is a clinical-stage biotechnology firm dedicated to finding and developing treatments that can change their lives. Rallybio has developed a portfolio of potential pharmaceutical candidates since its start in January 2018 that are now being developed to treat uncommon illnesses in the fields of hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. A group of highly skilled biopharma industry executives with in-depth knowledge of research, development, and rare diseases is advancing the company’s objective. Rallybio has offices in both New Haven, Connecticut, and Farmington, Connecticut, at the University of Connecticut’s Technology Incubation Program.